Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric IBD Long-term Registry
NL-OMON41540Phase 4Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in Crohn's disease, autoimmune colitis and indeterminate colitis (IC), sponsored by Janssen Pharmaceutical. Primary endpoints: Long-term safety and clinical status data collection, Adverse events and serious adverse events and 1 more. Started Dec 2009; status: recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseautoimmune colitisindeterminate colitis (IC)
Beyond the preview
Go deeper on NL-OMON41540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41540.